These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 21968130)

  • 21. Proteasome inhibition reduces donor-specific antibody levels.
    Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Brown E; Tevar A; Woodle ES
    Transplant Proc; 2009; 41(1):105-7. PubMed ID: 19249489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib is effective to treat acute humoral rejection after liver transplantation.
    Lee CF; Eldeen FZ; Chan KM; Wu TH; Soong RS; Wu TJ; Chou HS; Lee WC
    Transplant Proc; 2012 Mar; 44(2):529-31. PubMed ID: 22410063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
    Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
    Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of bortezomib for prevention and treatment of rejection in sensitized patients.
    Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D
    Clin Transpl; 2009; ():499-503. PubMed ID: 20524323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients.
    George JF; Kirklin JK; Shroyer TW; Naftel DC; Bourge RC; McGiffin DC; White-Williams C; Noreuil T
    J Heart Lung Transplant; 1995; 14(5):856-64. PubMed ID: 8800720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib for refractory antibody-mediated cardiac allograft rejection.
    Eckman PM; Thorsgard M; Maurer D; Kim Y; Alloway RR; Woodle ES
    Clin Transpl; 2009; ():475-8. PubMed ID: 20524318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of proteasome inhibition in sensitized transplant candidates.
    Everly MJ; Everly JJ; Terasaki PI
    Chin Med J (Engl); 2011 Mar; 124(5):771-4. PubMed ID: 21518574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib: a new player in pre- and post-transplant desensitization?
    Lemy A; Toungouz M; Abramowicz D
    Nephrol Dial Transplant; 2010 Nov; 25(11):3480-9. PubMed ID: 20826741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
    Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
    Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib for acute humoral rejection in two repeat transplant recipients.
    Hardinger KL; Alford K; Murillo D
    Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
    Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
    Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
    Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J
    Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasome inhibition for antibody-mediated rejection.
    Everly JJ; Walsh RC; Alloway RR; Woodle ES
    Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
    Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports.
    Sberro-Soussan R; Zuber J; Suberbielle-Boissel C; Legendre C
    Clin Transpl; 2009; ():433-8. PubMed ID: 20524311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-mediated rejection in heart transplant patients: long-term follow up of patients with high levels of donor-directed anti-DQ antibodies.
    Ticehurst EH; Molina MR; Frank R; Kearns J; Lal P; Goldberg LR; Tsai D; Wald J; Kamoun M
    Clin Transpl; 2011; ():409-14. PubMed ID: 22755439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.
    Wahrmann M; Haidinger M; Drach J; Geyeregger R; Kikić Z; Raab R; Säemann MD; Böhmig GA
    Clin Transpl; 2009; ():415-20. PubMed ID: 20524307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
    Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
    Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.